The Zenome project is a decentralized blockchain-driven database of genomic information. This platform supports the possibility to manage your genomic data while maintaining privacy and ability to make a profit from selling access to different parts of the genome. It will establish equal conditions for drug development and for the progress of scientic and medical technologies.
The Zenome project is a decentralized blockchain-driven database of genomic information.
Zenome platform supports the possibility to manage your genomic data while maintaining privacy and ability to make a profit from selling access to different parts of the genome. Zenome establishes equal conditions for drug development and for the progress of scientific and medical technologies.
The principal Zenome customers of genetic information are companies interested in genetic targeting such as Google, Facebook, Unilever and pharmaceutical companies.
Zenome DNA (ZNA) is a utility token on Zenome platform.
On the Zenome platform user is engaged in many types of different interactions throughout the system. These interactions take place at different system levels, don’t interfere with each other and involve different patterns of interactions. Thus, they should be represented as distinct entities that have different roles.
The participants who provide resources for the operation of this network receive payments for it in Zenome tokens.
|“||Development of MVP - IT - DEC 2017: Development of web-interface capable of uploading genetic data to the network and providing personalized genetic report.
The first service provider on the Zenome platform.
Pilot - MAR 2018: The establishment of a network for distributed storing of genetic information.
Development of a client application capable of uploading genetic data from user's PC.
B-version - MAY 2018: Using smart-contacts to enforce operations with genetic data: buying, selling, transferring.
Fund Zenome - JUN 2018: The establishment of Zenome Fund to support projects based on a platform.
The Main Committee of Zenome Fund would be established.
Lab partnership - SEP 2018: The establishment of a broad network of partnerships with genetic labs.
Collecting genetic material and adding these DNA samples to the network.
Achieve the size of 2 000 000 active users.
Creation of the Market - DEC 2018: Commercialization.
The start of the active genetic data exchange between the users.
Big Pharma partnership - MAR 2019: Reach a partnership agreement with Big Pharma.
Start developing personalized drugs based on the genetic data collected.
FMCG partnership - AUG 2019: Reach a partnership agreement with leading FMCG-companies.
Start developing personalized nutrition based on the genetic data collected.
|Yuri Nikolsky||Advisor in||https://www.linkedin.com/in/yurinikolsky/||Advisors||3.8|
|Richard Resnick||Senior advisor||https://www.linkedin.com/in/richardresnick/||Advisors||3.8|
|Alexey Gorbachev||Ph.D. in molecular biology and biochemistry||https://www.linkedin.com/in/alexey-gorbachev-24b5305b/||Founder||3.8|
|Nikolay Kulemin||Ph.D. in bioinformatics||https://www.linkedin.com/in/nikolay-kulemin-50ab47a9/||Founder||3.8|
|Vladimir Naumov||Genomic data scientist||https://www.linkedin.com/in/vladimir-naumov-8285a25b/||Team||3.8|
|Anastasia Gubina||Project Manager||https://www.linkedin.com/in/anastasia-gubina-97b13b154/||Team||3.8|
|Alexey Kuzmenkov||Researcher, Ph.D. in biochemistry||Team||3.8|